Back

CAMKV Kinase Signaling Is a Novel Therapeutic Avenue with Prognostic Relevance in Neuroblastoma

Yu, Y.; Zhao, Y.; Shi, Z.; Cheng, F.; Wang, L. L.; Choi, J. M.; Li, K.; Silverman, D.; Qi, D.; Wang, J.; Agarwal, S.; Rood, B.; Dome, J. S.; Fabbri, M.; Yi, J. S.; Wu, E.; Jung, S. Y.; Zhang, C.; Yang, J.

2024-02-22 cancer biology
10.1101/2024.02.19.581040 bioRxiv
Show abstract

Neuroblastoma (NB) can be a highly aggressive malignancy in children. However, the precise mechanisms driving NB tumorigenesis remain elusive. This study revealed the critical role of CREB phosphorylation in NB cell proliferation. By employing a CRISPR-Cas9 knockout screen targeting calcium/calmodulin-dependent protein kinase (CaMK) family members, we identified the CaM kinase-like vesicle-associated (CAMKV) protein as a kinase that mediates direct phosphorylation of CREB to promote NB cell proliferation. CAMKV was found to be a transcriptional target of MYCN/MYC in NB cells. CAMKV knockout and knockdown effectively suppressed NB cell proliferation and tumor growth both in vitro and in vivo. Bioinformatic analysis revealed that high CAMKV expression is significantly correlated with poor patient survival. High-risk NB frequently had high CAMKV protein levels by Immunohistochemical staining. Integrated transcriptomic and proteomic analyses of CAMKV knockdown cells unveiled downstream targets involved in CAMKV-regulated phosphorylation and signaling pathways, many of which are linked to neural development and cancer progression. We identified small molecule inhibitors targeting CAMKV and further demonstrated the efficacy of one inhibitor in suppressing NB tumor growth and prolonging the survival of mice bearing xenografted tumors. These findings reveal a critical role for CAMKV kinase signaling in NB growth and identified CAMKV kinase as a potential therapeutic target and prognostic marker for patients with NB.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

1
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.1%
8.6%
2
eLife
5422 papers in training set
Top 11%
6.9%
3
Molecular Cancer
14 papers in training set
Top 0.1%
6.9%
4
Advanced Science
249 papers in training set
Top 3%
4.9%
5
Nature Communications
4913 papers in training set
Top 32%
4.9%
6
Genomics, Proteomics & Bioinformatics
171 papers in training set
Top 2%
3.1%
7
National Science Review
22 papers in training set
Top 0.5%
2.8%
8
Cell Discovery
54 papers in training set
Top 2%
2.8%
9
Cell Research
49 papers in training set
Top 0.7%
2.6%
10
Molecular Therapy
71 papers in training set
Top 1.0%
2.5%
11
Protein & Cell
25 papers in training set
Top 0.8%
2.4%
12
Cell Reports
1338 papers in training set
Top 20%
2.1%
50% of probability mass above
13
Oncogene
76 papers in training set
Top 0.9%
1.9%
14
Theranostics
33 papers in training set
Top 0.5%
1.8%
15
iScience
1063 papers in training set
Top 13%
1.8%
16
The Innovation
12 papers in training set
Top 0.3%
1.8%
17
Cancer Cell
38 papers in training set
Top 0.9%
1.8%
18
Cell Death & Disease
126 papers in training set
Top 0.9%
1.7%
19
Clinical and Translational Medicine
30 papers in training set
Top 0.3%
1.7%
20
Science China Life Sciences
26 papers in training set
Top 0.9%
1.7%
21
Scientific Reports
3102 papers in training set
Top 63%
1.4%
22
Communications Biology
886 papers in training set
Top 12%
1.4%
23
PLOS ONE
4510 papers in training set
Top 60%
1.2%
24
Frontiers in Oncology
95 papers in training set
Top 3%
0.9%
25
International Journal of Biological Macromolecules
65 papers in training set
Top 3%
0.9%
26
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
27
Cell Genomics
162 papers in training set
Top 6%
0.8%
28
Neoplasia
22 papers in training set
Top 0.6%
0.8%
29
Cell Death Discovery
51 papers in training set
Top 1%
0.8%
30
Cancer Letters
32 papers in training set
Top 0.7%
0.8%